What clinical and economic evidence do US payers prefer to drive formulary decisions? How can you optimise your chances of preferential access in the US with the right evidence? How should evidence be generated, synthesised, and presented for the US market?
In this webinar, Clare Foy (Director – Global Market Access, Mtech Access) interviews colleagues Nicole Lodowski (Managing Director, Petauri Evidence) and Bob Nordyke (Senior Advisor, Petauri Evidence) about US payer evidence challenges.
In this Global Whispers webinar, we explore the evolving evidence needs for US payers. Nicole and Bob share unique perspectives around their extensive experience of driving evidence strategies for US pharmaceutical and medical device launches. Additionally, Nicole and Bob share a ‘sneak peek’ of exclusive insights from a recent Petauri US payer insights survey conducted to better understand the evidence landscape from the US payers’ perspective.
They explore:
- The evolving payer evidence landscape in the US
- Preferences for clinical and economic evidence by US payers
- Key differences between the US and other global markets with regard to evidence, HEOR, and market access
- Opportunities and challenges when launching new medicines/medical devices/diagnostics in the US
- Innovative perspectives on evidence planning and strategy for the US market
- US payers’ perspectives, with exclusive insights from Petauri Evidence’s 2024 US payer survey
Listen to the podcast:
This episode is also available as a podcast. Listen below or search ‘Pharma Market Access Insights – from Mtech Access’ on Spotify, Apple Podcasts or Google Podcasts.
More about our speakers
Nicole Lodowski (Managing Director, Petauri Evidence)
Nicole brings nearly 15 years of experience in the biopharmaceutical industry, including roles spanning both manufacturer and strategic consultancy organisations. Her leadership in building and developing US-based market access and HEOR teams within global consulting organisations has equipped her with a comprehensive understanding of evidence generation strategy globally across diverse functions and stakeholders. As Managing Director, Nicole leads a world-class team of technical and strategic experts dedicated to delivering innovative solutions for clients that are built on a foundation of robust evidence. Prior to Petauri, Nicole held leadership positions within market access and HEOR strategic consultancies. She earned her Master of Public Health (MPH), with a concentration on International and Community Public Health at New York University.
Bob Nordyke (Senior Advisor, Petauri Evidence)
Bob, a seasoned leader and expert in health economics in the pharmaceutical industry, brings over 25 years of invaluable experience to Petauri. Before joining Petauri Evidence, Bob held prominent research positions across the industry. He served as the Global Payer Lead in oncology and later as the Therapeutic Area Head for inflammation within Amgen’s Global Health Economics group. Additionally, Bob served as the Vice President at Angion Biomedica, spearheading global value strategies, evidence generation, and business development for treatments targeting rare diseases. Bob’s leadership extends to founding the health economics practices at several leading market access consultancies. Most recently, Bob served as Vice President of Research at the National Pharmaceutical Council, leading impactful economics, pricing, and value assessment initiatives. Bob has also shared his expertise as a Lecturer at the USC Sol Price School of Public Policy and as an Adjunct Professor at the UCLA Fielding School of Public Health. He holds a BS in Engineering from Rose-Hulman Institute of Technology, an MS in Engineering from the University of Texas, Austin, and a PhD in Public Policy Analysis (Health Policy) from the Pardee RAND Graduate School.
More about Petauri
The Petauri Evidence Team collaborate with pioneering clients to assist them in unlocking access potential through purposeful evidence, driving value beyond traditional HEOR offerings and deliverables. Working closely with Mtech Access and other business units within the Petauri platform, Petauri Evidence provide clients with a truly collaborative and cross-functional approach to evidence generation throughout the product lifecycle, with access as the guiding principle.
The Global Whispers webinar series
This webinar is part of our Global Whispers series where we explore global market access trends and challenges facing the Pharmaceutical and Medtech industries and offer insights into key launch markets.
Our previous webinars are available on demand:
- June 2024: ‘De-mystifying the NHS – What you need to know about the NHS as a market for your health technology’ with guest speaker Dr Faris Al-Ramadani (PCN Clinical Director and GP Partner in the NHS and HealthTech and Venture Capital Consultant)
- March 2024: ‘Market access and reimbursement in Canada – changes at CADTH’ with guest speaker Don Husereau (Adjunct Professor of Medicine, The University of Ottawa)
- January 2024: ‘Setting your product up for success – commercialisation strategy for the US market’ with guest speaker Janice MacLennan (Pharma and Medtech brand strategist and founder of NMBLR)
- October 2023: ‘Market Access in Italy: Exploring the potential impact of the AIFA reforms’ with guest speaker Prof. Fabrizio Gianfrate (Professor of HEOR and Ex-Payer)
- August 2023: ‘Artificial intelligence (AI) in clinical trials: Implications for evidence synthesis and market access’ with guest speaker George Magrath (CEO, Lexitas)
- July 2023: ‘Market access in the German-speaking markets’ with guest speaker Dr Stefan Walzer (CEO, President & Founder at MArS Market Access & Pricing Strategy GmbH)
- June 2023: ‘Market access for digital therapies and digital medicines’ with guest speaker Shefali Shah (Global VP, Market Value and Commercial Effectiveness – MindMaze)
- May 2023: ‘A global market access journey: What it takes to bring a cannabinoid pharmaceutical to market’ with guest speaker Michael Sassano (CEO – SOMAÍ Pharmaceuticals)
